Novartis Share Price | Novartis Stock Screener
NOVARTIND
Pharmaceuticals
Share Price NSE
₹1487.70
▲
72.00 (5.09%)
Share Price BSE
₹1488.00
▲
73.75 (5.21%)
As of May 27, 2026, the Novartis share price (NSE: NOVARTIND) is ₹1,487.70 on NSE and ₹1,488.00 on BSE, up 5.09% from the previous close, with shares trading between ₹1,412.20 and ₹1,498.00, and a 52-week range of ₹962.00–₹1,487.70.
Check NOVARTIND 52-week chart for the annual price range and momentum.
Use the Novartis stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Novartis Market Cap
₹3,673.25 Cr.
NOVARTIND P/E Ratio (TTM)
37.47
Novartis P/B Ratio
4.27
EPS (TTM)
₹37.74
Dividend Yield
-
Debt to Equity
0.01
NOVARTIND 52 Week High
₹1487.70
Novartis 52 Week Low
₹962.00
Operating Margin
27.00%
Profit Margin
26.84%
NOVARTIND Revenue (TTM)
₹354.00
EBITDA
₹94.00
Net Income
₹95.00
Total Assets
₹978.00
Total Equity
₹818.00
Novartis Share Price Chart
Screen Novartis share price with an interactive chart. Analyse NOVARTIND price trends and volatility across different timeframes.
Novartis Company Profile - Fundamental Screener
Screen Novartis company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for NOVARTIND shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE234A01025
Novartis Balance Sheet Screener
Screen NOVARTIND balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 978 | 948 | 925 | 983 | 958 | 1,002 | 1,078 | 982 | 1,111 | 1,150 |
| Current Assets | 768 | 746 | 699 | 677 | 709 | 723 | 813 | 807 | 952 | 973 |
| Fixed Assets | 3 | 5 | 7 | 19 | 24 | 64 | 76 | 15 | 5 | 6 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 16 | 21 | 23 | 48 | 50 | 132 | 124 | 38 | 47 | 47 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 818 | 785 | 745 | 776 | 692 | 711 | 721 | 759 | 734 | 920 |
| Share Capital | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 14 |
| Reserves & Surplus | 806 | 773 | 733 | 763 | 679 | 699 | 708 | 747 | 721 | 906 |
Novartis Income Statement Screener - Profit & Revenue Analysis
Screen Novartis income statement and profit fundamentals.
Analyze NOVARTIND quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Novartis share price evaluation.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 354 | 398 | 397 | 437 | 433 | 414 | 474 | 569 | 736 | 727 | 771 | 981 |
| Expenses | 260 | 265 | 270 | 314 | 373 | 355 | 426 | 478 | 570 | 631 | 656 | 877 |
| EBITDA | 94 | 133 | 127 | 123 | 60 | 60 | 48 | 91 | 166 | 96 | 115 | 104 |
| Operating Profit % | 27.00% | 26.00% | 19.00% | 17.00% | 7.00% | 7.00% | 3.00% | 3.00% | -1.00% | 4.00% | 5.00% | 0.00% |
| Depreciation | 2 | 2 | 3 | 6 | 10 | 12 | 13 | 3 | 3 | 4 | 4 | 4 |
| Interest | 1 | 1 | 2 | 2 | 5 | 8 | 6 | 2 | 6 | 1 | 0 | 0 |
| Profit Before Tax | 130 | 130 | 123 | 115 | -4 | 40 | 29 | 86 | 158 | 92 | 111 | 93 |
| Tax | 35 | 30 | 38 | 12 | 0 | 19 | 19 | 34 | 79 | 35 | 39 | 14 |
| Net Profit | 95 | 101 | 85 | 103 | -4 | 21 | 10 | 52 | 78 | 57 | 73 | 79 |
| EPS | 37.74 | 40.87 | 34.50 | 41.86 | -1.51 | 8.46 | 4.08 | 20.97 | 28.43 | 19.10 | 62.04 | 24.75 |
Novartis Cash Flow Screener - Liquidity Fundamentals
Screen NOVARTIND cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 75 | 113 | 45 | 39 | -69 | -23 | -194 | 161 | -41 | 57 |
| Investing Activities | -3 | 33 | -153 | 87 | 95 | 56 | 274 | 69 | 424 | -631 |
| Financing Activities | -64 | -121 | -31 | -36 | -37 | -41 | -30 | -268 | -332 | -39 |
| Net Cash Flow | 7 | 26 | -139 | 90 | -11 | -9 | 50 | -38 | 51 | -613 |
Novartis Shareholding Pattern Screener
See Novartis shareholding pattern with promoter, FII, and DII holdings.
Check Novartis promoter holding and ownership changes for NOVARTIND on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% |
| FII Holding | 0.17% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% |
| DII Holding | 0.53% | 0.53% | 0.53% | 0.53% | 0.64% | 0.53% | 0.53% | 0.53% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 23.25% | 23.11% | 22.95% | 22.92% | 22.67% | 22.95% | 23.04% | 23.05% |
| Other Holding | 5.36% | 5.49% | 5.66% | 5.68% | 5.83% | 5.65% | 5.57% | 5.55% |
| Shareholder Count | 38,116 | 39,133 | 39,040 | 39,353 | 39,468 | 41,239 | 39,265 | 39,596 |
Novartis Share Dividend Screener - Share Yield Analysis
Check Novartis dividend history with payout and yield data.
View Novartis dividend details including ex-dates and amounts for NOVARTIND stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹47.50 | 7.07% |
| 2022-March | ₹10.00 | 1.77% |
| 2021-March | ₹10.00 | 1.70% |
| 2020-March | ₹10.00 | 1.81% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Novartis Stock Index Membership
See which indices include Novartis stock.
Check NOVARTIND index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
Novartis Market Events Screener - Corporate Actions
Get Novartis corporate actions including splits, bonuses, and buybacks.
Check Novartis stock events that may affect NOVARTIND share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-05-12 | 2026-05-12 | Quarterly Result Announcement | NA | 21.81% |
| 2026-01-28 | 2026-01-28 | Quarterly Result Announcement | NA | 3.23% |
| 2025-10-28 | 2025-10-28 | Quarterly Result Announcement | NA | -3.77% |
| 2025-07-31 | 2025-07-31 | Annual General Meeting | NA | 24.87% |
| 2025-07-29 | 2025-07-29 | Quarterly Result Announcement | NA | -0.92% |
| 2025-07-23 | 2025-07-23 | Dividend | ₹ 25.00 /share | 33.11% |
| 2025-05-09 | 2025-05-09 | Quarterly Result Announcement | NA | -3.94% |
| 2025-01-28 | 2025-01-28 | Quarterly Result Announcement | NA | -4.09% |
| 2024-10-25 | 2024-10-25 | Quarterly Result Announcement | NA | -9.21% |
| 2024-07-31 | 2024-07-31 | Annual General Meeting | NA | 11.66% |
| 2024-07-23 | 2024-07-24 | Dividend | ₹ 25.00 /share | 5.99% |
| 2023-07-20 | 2023-07-21 | Dividend | ₹ 37.50 /share | 32.63% |
| 2023-07-20 | 2023-07-21 | Dividend | ₹ 10.00 /share | 32.63% |
| 2022-07-20 | 2022-07-22 | Dividend | ₹ 10.00 /share | 7.03% |
| 2021-08-17 | 2021-08-20 | Dividend | ₹ 10.00 /share | -11.14% |
Novartis Competitors Screener - Peer Comparison
Screen NOVARTIND competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 442,509 | 38.37 | 58,220 | 6.38% | 11,565 | 54.66 |
| Divis Laboratories | 180,452 | 69.82 | 10,560 | 8.73% | 2,520 | 59.28 |
| Torrent Pharmaceuticals | 153,580 | 70.46 | 13,753 | 19.18% | 2,028 | 60.91 |
| Cipla | 114,559 | 29.64 | 27,712 | -2.46% | 3,783 | 64.86 |
| Dr Reddys Laboratories | 110,089 | 26.69 | 33,593 | -0.44% | 3,998 | 54.22 |
| Zydus Life Science | 109,257 | 21.19 | 26,720 | 13.65% | 5,242 | 75.42 |
| Lupin | 104,041 | 19.33 | 27,488 | 19.98% | 5,345 | 46.91 |
| Mankind Pharma | 99,915 | 51.52 | 14,278 | 12.03% | 1,750 | 55.29 |
| Aurobindo Pharma | 83,397 | 24.27 | 33,385 | 3.21% | 3,376 | 47.24 |
| Laurus Labs | 74,592 | 83.31 | 6,813 | 21.03% | 884 | 80.70 |
Novartis Company Announcements - News Screener
Screen NOVARTIND latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-23 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-20 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-05-20 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | - |
| 2026-05-16 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-15 | Corrigendum To The Notice Of Postal Ballot Issued On April 16 2026 For The Appointment Of Ms. Gowree Gokhale (DIN: 09351661) As An Independent Director. | - |
| 2026-05-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-12 | Integrated Financial Results For The Quarter And Financial Year Ended March 31 2026. | - |
| 2026-05-12 | Board Meeting Outcome for Outcome Of The Board Meeting Held On Tuesday May 12 2026 To Approve The Audited Financial Results For The Quarter And The Financial Year Ended March 31 2026. | - |
| 2026-04-23 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-04-16 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - |
| 2026-04-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-04-07 | Disclosure Under Regulation 31(4) Of The SEBI (Substantial Acquisition Of Shares And Takeover Regulations 2011) | - |
| 2026-03-31 | Board Meeting Intimation for Intimation Of Meeting Of The Board Of Directors Of Novartis India Limited (The Company) And Closure Of Trading Window. | - |
| 2026-03-31 | Closure of Trading Window | - |
| 2026-03-30 | Intimation Of The Receipt Of Delhi High Court Order Admitting Company Petition In The Matter Of Novartis India Limited Vs. Commissioner Of Trade And Taxes (W.P.(C) 3892/2026) | - |
| 2026-03-27 | Intimation Under Reg 30 Of SEBI LODR Of Receipt Of TDS Order As Per Income Tax Act | - |
| 2026-03-27 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-03-27 | Announcement under Regulation 30 (LODR)-Cessation | - |